You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Under the non-exclusive partnership, Emedgene will integrate its genome interpretation application into Illumina's TruSight software suite.
With its recent $50 million VC round, the British bioinformatics firm is targeting growth in new applications as it accelerates tertiary data analysis.
The new CompStor Insight combines hardware and software in one plug-and-play package and complements the vendor's Novos DNA assembly tool.
PierianDx will integrate its cancer profiling assays with Pillar Biosciences' PiVAT bioinformatics pipeline on a GPDR-compliant platform.
The deal between the two Israeli bioinformatics companies gives BATM a minority stake in Geneyx.
The informatics firm is working on an RUO COVID-19 susceptibility risk score to inform researchers and policymakers itching to restart the US economy.
The German hospital will build interpretation and reporting on the PierianDx Clinical Genomics Workspace for two Illumina assays.
Now valued at $5 billion, the company will apply the new funding to continue its expansion in diabetes, depression, and cardiology.
The deal will allow users of MGI's DNBSEQ sequencers to convert previously validated assays to the platform and access Sophia's analytics technology.
Italy's Dante Labs is building one of Europe's largest genomic labs and leading an effort to sequence 100,000 whole genomes around the Mediterranean.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.